therapeutics.23andme.com Open in urlscan Pro
2606:4700::6810:b649  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * Careers
 * Investors
 * Contact

 * About
 * Our Platform
 * Pipeline & Programs
   * Pipeline OverviewSee the 23andMe Therapeutics pipeline in full
   * 23ME-00610Clinical-stage therapeutic antibody designed to restore the
     immune system’s ability to kill cancer cells
   * 23ME-01473Clinical-stage antibody targeting ULBP6 to induce immune
     activation through dual mechanisms that may restore anti-tumor immunity.
 * Collaborations
 * News & Research

 * About Us
 * Our Platform
 * Pipeline & Programs
   * Overview
   * 23ME-00610
   * 23ME-01473
 * Collaborations
 * News & Research
 * Careers
 * Contact
 * Investors


TOMORROW’S MEDICINES ARE IN OUR GENES.


WE ARE AN INTEGRATED CLINICAL-STAGE BIOTECH COMPANY TURNING DATA AT SCALE INTO
NEW TREATMENTS FOR PATIENTS.





WE TRANSLATE BIOLOGICAL INSIGHTS FROM THE WORLD'S LARGEST RECONTACTABLE HUMAN
GENETIC DATABASE INTO POTENTIALLY SIGNIFICANT NEW THERAPIES FOR PATIENTS WITH
SERIOUS UNMET NEED, FOCUSING ON CANCER AND IMMUNOLOGICAL AND INFLAMMATORY
DISEASES.


OUR PLATFORM

Powered by the world’s largest recontactable platform of genetic and phenotypic
data, and an experienced team with the ability to leverage it, we focus on
developing therapeutic antibodies with high-value targets that are central
mediators of biological processes.

Explore Our Platform


CLINICAL PROGRAMS

23andMe Therapeutics has advanced two immuno-oncology programs into the clinic.
23ME-00610 is a first-in-class clinical investigational therapeutic antibody
generated in-house and designed to restore the ability of the body’s immune
cells to kill cancer cells by blocking the immunosuppressive checkpoint receptor
CD200R1. It is currently enrolling the Phase 2a portion of a Phase 1/2a study.

 

23ME-01473 is an NK cell-activating investigational therapeutic antibody
targeting the NKG2D ligand ULBP6.

Learn More About Our Pipeline and Programs


"We look forward to leveraging our unique database, along with advancements in
AI and ML, to further advance therapeutic programs at 23andMe, both
independently and with collaborators."

Anne Wojcicki

CEO & Co-Founder


COLLABORATIONS

We seek development collaborators to help us realize the full clinical and
commercial potential of our immuno-oncology programs. We also seek innovative,
future-forward research teams to embark with us on the discovery and early
development of novel, genetically validated targets. Lastly, we invite inquiries
from teams interested in leveraging our database for in silico discovery
partnerships.

Collaborate on our I/O clinical assets
Help us pursue targets in I&I
Learn about leveraging our data for in silico R&D


LATEST RESEARCH

View All Research
23ME-00610
Research

SAFETY, EFFICACY, AND PKPD OF 23ME-00610, A FIRST-IN-CLASS ANTI-CD200R1
ANTIBODY, IN PATIENTS WITH ADVANCED OR...

Jun 3, 2024
Read more
23ME-00610
Research

SAFETY, EFFICACY, AND PKPD OF 23ME-00610, A FIRST-IN-CLASS ANTI-CD200R1
ANTIBODY, IN PATIENTS WITH ADVANCED NEUROENDOCRINE...

Jun 1, 2024
Read more
23ME-01473
Research

DISCOVERY OF ULBP6 AS A NOVEL IMMUNO-ONCOLOGY TARGET USING PLEIOTROPIC SIGNALS
FROM 23ANDME’S GENETIC AND...

Apr 17, 2024
Read more
23ME-01473
Research

23ME-01473, A NOVEL ANTI-ULBP6/2/5 MONOCLONAL ANTIBODY, REINVIGORATES ANTI-TUMOR
NK CELL FUNCTION THROUGH NKG2D AND FCΓRIIIA...

Apr 8, 2024
Read more
23ME-00610
Research

NEW INSIGHTS INTO TARGETING THE CD200R1 PATHWAY IN T AND NK CELLS USING
23ME-00610 AS...

Apr 8, 2024
Read more
Company
Research

AN ENGINEERED MOUSE MODEL THAT GENERATES A DIVERSE REPERTOIRE OF ENDOGENOUS,
HIGH-AFFINITY COMMON LIGHT CHAIN...

Feb 8, 2024
Read more
Company
Research

THE METABOLIC ROLE OF MAP3K15: GENETIC AND PHENOTYPIC INSIGHTS FROM THE 23ANDME
RESEARCH DATABASE AND...

Jan 10, 2024
Read more
Blog
Research

THE POWER OF SCALE IN DRUG DEVELOPMENT

Jan 10, 2024
Read more
23ME-00610
Research

FIRST-IN-CLASS ANTI-CD200R1 ANTIBODY 23ME-00610 IN PATIENTS WITH ADVANCED SOLID
MALIGNANCIES: PHASE 1 POSTER

Nov 3, 2023
Read more
 * 1
 * 2
 * 3

SERVICES

 * Health + Ancestry
 * Ancestry Service
 * 23andMe+ Premium
 * 23andMe+ Total Health
 * Gifts

COMPANY

 * Investors
 * About Us
 * Diversity, Equity, & Inclusion
 * Media Center
 * Blog
 * Genetics Learning Hub
 * Careers
 * Refer a Friend
 * Return Policy
 * Customer Care
 * FSA/HSA Eligibility

LEGAL

 * Important Test Info
 * Terms of Service
 * Privacy Statement
 * Data Protection
 * Family Considerations
 * Research Consent
 * Individual Data Consent
 * Biobanking Consent
 * Cookie Policy
 * Cookie Choices
 * Patent Information
 * Report a Security Issue
 * Consumer Health Data Privacy Policy

PARTNER WITH US

 * Healthcare Professionals
 * Education
 * Scientists
 * Therapeutics

DOWNLOAD APP




DOWNLOAD APP




©2024 23andMe, Inc. All rights reserved.

RECENT NEWS

Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1
antibody, in patients with advanced neuroendocrine cancers.

Learn more

RECENT NEWS

23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy
Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Mee

Learn more

RECENT NEWS

Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1
antibody, in patients with advanced or metastatic ovarian cancer.

Learn more

RECENT NEWS

Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1
antibody, in patients with advanced neuroendocrine cancers.

Learn more

RECENT NEWS

23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy
Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Mee

Learn more

RECENT NEWS

Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1
antibody, in patients with advanced or metastatic ovarian cancer.

Learn more

RECENT NEWS

Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1
antibody, in patients with advanced neuroendocrine cancers.

Learn more
 * 1
 * 2
 * 3